We identified oncogenic TERT amplifications in 44% (8/18) of intimal sarcoma (INTS) and TERT promoter mutations in 79% (38/48) of MRLS, 46% (24/52) of SFT, and 35% (5/14) of dedifferentiated chondrosarcoma (DDCHS). Here, TERT is linked to chondrosarcoma.